What causes anemia in multiple myeloma?

What causes anemia in multiple myeloma?

Multiple myeloma triggers an overgrowth of plasma cells in the bone marrow. Plasma cells are white blood cells that produce and secrete antibodies. Too many of these cells in the bone marrow crowd and decrease the number of normal blood-forming cells. This response causes a low red blood cell count.

Does multiple myeloma cause iron deficiency anemia?

Multiple myeloma is a non-curable B cell malignancy in which iron metabolism plays an important role. Patients with this disorder almost universally suffer from a clinically significant anemia, which is often symptomatic, and which is due to impaired iron utilization.

How long can you take Revlimid for multiple myeloma?

Results showed that patients receiving Revlimid lived 39 months without their disease worsening, compared with 20 months for the observation arm. This translated into a 54% reduction in the risk of disease progression or death.

Does multiple myeloma affect red blood cells?

Shortages of red blood cells, white blood cells, and blood platelets are common in multiple myeloma and might lead to other symptoms. Anemia: A reduced number of red blood cells that can cause weakness, a reduced ability to exercise, shortness of breath, and dizziness.

How long can a person take Revlimid?

Take this medication by mouth with or without food as directed by your doctor, usually once daily. Swallow this medication whole with water. For treatment of certain conditions, you may be instructed to take this medication in cycles (once daily for 21 days, then stopping the medication for 7 days).

Which is better lenalidomide or Revlimid for multiple myeloma?

January 18, 2019. by. Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy and, in some patients, also extends overall survival, a Phase 3 trial shows.

How is Revlimid used to treat bone marrow cancer?

It promotes immune responses to help slow tumor growth. Revlimid is used to treat multiple myeloma (bone marrow cancer), either in combination with another medicine or after stem cell transplant. Revlimid is also used to treat anemia (a lack of red blood cells) in patients with myelodysplastic syndrome caused by an abnormal chromosome.

What causes anemia in people with multiple myeloma?

Anemia may not only be caused by multiple myeloma, but may also be caused by the following: These treatments are known to cause anemia in a significant number of patients: Revlimid®, alone or in combination. Kyprolis®, alone or in combination. Pomalyst®, alone or in combination.

What are the side effects of multiple myeloma treatment?

Thrombocytopenia can also be a side effect of treatments for myeloma, including the proteasome inhibitors Velcade®, Kyprolis, and Ninlaro®, and the immunomodulatory drugs Revlimid and Pomalyst. How Is Anemia Treated? If the anemia is a side effect of treatment, your physician may adjust the dose and/or schedule of your therapy